JP2010534469A - Ｋｄｒ指向性標的化結合物質およびその使用 - Google Patents

Ｋｄｒ指向性標的化結合物質およびその使用 Download PDF

Info

Publication number
JP2010534469A
JP2010534469A JP2010517493A JP2010517493A JP2010534469A JP 2010534469 A JP2010534469 A JP 2010534469A JP 2010517493 A JP2010517493 A JP 2010517493A JP 2010517493 A JP2010517493 A JP 2010517493A JP 2010534469 A JP2010534469 A JP 2010534469A
Authority
JP
Japan
Prior art keywords
antibody
kdr
targeted binding
binding agent
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2010517493A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010534469A5 (OSRAM
Inventor
バリー，シモン，トーマス
ベディアン，ヴァヘ
ヘドバーグ，ブラッドリー
カン，ジャスパル，シン
チョウ，チン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of JP2010534469A publication Critical patent/JP2010534469A/ja
Publication of JP2010534469A5 publication Critical patent/JP2010534469A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2010517493A 2007-07-25 2008-07-23 Ｋｄｒ指向性標的化結合物質およびその使用 Pending JP2010534469A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US95180507P 2007-07-25 2007-07-25
PCT/GB2008/050615 WO2009013543A2 (en) 2007-07-25 2008-07-23 Targeted binging agents directed to kdr and uses thereof - 035

Publications (2)

Publication Number Publication Date
JP2010534469A true JP2010534469A (ja) 2010-11-11
JP2010534469A5 JP2010534469A5 (OSRAM) 2011-09-08

Family

ID=40281893

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010517493A Pending JP2010534469A (ja) 2007-07-25 2008-07-23 Ｋｄｒ指向性標的化結合物質およびその使用

Country Status (6)

Country Link
US (1) US8119130B2 (OSRAM)
EP (1) EP2183028A2 (OSRAM)
JP (1) JP2010534469A (OSRAM)
AU (1) AU2008278803A1 (OSRAM)
CA (1) CA2694396A1 (OSRAM)
WO (1) WO2009013543A2 (OSRAM)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8119130B2 (en) 2007-07-25 2012-02-21 Medimmune Limited Targeted binding agents directed to KDR and uses thereof—035
JO3375B1 (ar) * 2010-11-08 2019-03-13 Regeneron Pharma أجسام مضادة بشرية للجين a1 الشبيه بعامل النخر الورمي (tl1a)
EP2673294B1 (en) 2011-02-10 2016-04-27 Roche Glycart AG Mutant interleukin-2 polypeptides
EA201892619A1 (ru) 2011-04-29 2019-04-30 Роше Гликарт Аг Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
AU2012318246B2 (en) 2011-11-02 2015-10-15 Apexigen, Inc. Anti-KDR antibodies and methods of use
CN103087192B (zh) * 2011-11-02 2015-02-04 埃派斯进有限公司 抗-kdr抗体和使用方法
US20140044675A1 (en) 2012-08-10 2014-02-13 Roche Glycart Ag Interleukin-2 fusion proteins and uses thereof
JO3462B1 (ar) 2012-08-22 2020-07-05 Regeneron Pharma أجسام مضادة بشرية تجاه gfr?3 وطرق لاستخدامها
KR101935088B1 (ko) 2012-08-24 2019-01-04 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 Ror1 암을 치료하고 전이를 저해하는데 이용을 위한 항체와 백신
DK2895512T3 (en) * 2012-09-12 2018-10-15 Neurimmune Holding Ag Antibodies specific for human islet amyloid polypeptide (HIAPP) and uses thereof
BR112016018288A2 (pt) 2014-02-06 2017-10-10 Hoffmann La Roche proteínas de fusão de interleucina 2 e uso das mesmas
TW201718641A (zh) * 2015-06-30 2017-06-01 偉東 姜 抗血管內皮生長因子受體２（ｖｅｇｆｒ２）抗體
IL299099B2 (en) 2016-06-27 2025-07-01 Univ California Cancer treatment combinations
WO2018148447A1 (en) * 2017-02-08 2018-08-16 Adimab, Llc Antibody heavy chain variable domains targeting the nkg2d receptor
JP2020506971A (ja) 2017-02-08 2020-03-05 ドラゴンフライ セラピューティクス， インコーポレイテッド ナチュラルキラー細胞の活性化のための多重特異性結合タンパク質およびがんを処置するためのその治療的使用
SG11201907646YA (en) 2017-02-20 2019-09-27 Dragonfly Therapeutics Inc Proteins binding her2, nkg2d and cd16
CA3054067A1 (en) 2017-03-14 2018-09-20 Five Prime Therapeutics, Inc. Antibodies binding to vista at acidic ph
WO2019084053A1 (en) * 2017-10-24 2019-05-02 Magenta Therapeutics, Inc. COMPOSITIONS AND METHODS FOR DEPLOYING CD117 + CELLS
CA3079215A1 (en) 2017-10-24 2019-05-02 Magenta Therapeutics, Inc. Compositions and methods for the depletion of cd117+ cells
AU2018355244B2 (en) 2017-10-24 2025-08-28 Crispr Therapeutics Ag Compositions and methods for the depletion of CD117+ cells
PE20210375A1 (es) 2018-02-08 2021-03-02 Dragonfly Therapeutics Inc Terapia de combinacion del cancer que incluye proteinas de union multiespecificas que activan a las celulas asesinas naturales
FI3749346T3 (fi) 2018-02-08 2024-09-04 Dragonfly Therapeutics Inc Nkg2d-reseptoriin kohdistuvat vasta-aineen vaihtelevan domeenin yhdistelmät
MX2020008684A (es) 2018-02-20 2020-12-07 Dragonfly Therapeutics Inc Proteinas de union multiespecificas que se unen a cd33, nkg2d y cd16 y metodos de uso.
PE20210290A1 (es) 2018-03-21 2021-02-11 Five Prime Therapeutics Inc ANTICUERPOS DE UNION A VISTA A pH ACIDO
BR112021000303A2 (pt) 2018-07-11 2021-04-13 Five Prime Therapeutics, Inc. Anticorpos que se ligam a vista em ph ácido
EA202091888A1 (ru) 2018-08-08 2020-10-23 Драгонфлай Терапьютикс, Инк. Вариабельные домены антител, нацеленные на рецептор nkg2d
US12384851B2 (en) 2018-08-08 2025-08-12 Dragonfly Therapeutics, Inc. Multi-specific binding proteins that bind BCMA, NKG2D and CD16, and methods of use
JP7482363B2 (ja) 2018-08-08 2024-05-14 ドラゴンフライ セラピューティクス， インコーポレイテッド Ｎｋｇ２ｄ、ｃｄ１６及び腫瘍関連抗原に結合するタンパク質
TW202208428A (zh) 2020-05-06 2022-03-01 美商蜻蜓醫療公司 結合ｎｋｇ２ｄ、ｃｄ１６及ｃｌｅｃ１２ａ之蛋白質
EP4301774A4 (en) 2021-03-03 2025-08-13 Dragonfly Therapeutics Inc METHODS OF TREATING CANCER USING MULTI-SPECIFIC BINDING PROTEINS THAT BIND TO NKG2D, CD16, AND A TUMOR-ASSOCIATED ANTIGEN
JP2024528038A (ja) 2021-07-29 2024-07-26 ソノマ バイオセラピューティクス， インコーポレイテッド 調節性ｔ細胞を標的として自己免疫疾患を処置するための滑膜細胞外マトリックス特異的キメラ抗原受容体

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005500034A (ja) * 2001-06-20 2005-01-06 プロション バイオテク リミテッド 受容体型タンパク質チロシンキナーゼ活性化を遮断する抗体、そのスクリーニング方法、及びその使用
EP1411983A4 (en) * 2001-06-26 2006-06-21 Imclone Systems Inc BISPECIFIC ANTIBODIES BINDING TO VEGF RECEPTORS
DK1487856T3 (da) * 2002-03-04 2010-10-18 Imclone Llc KDR-specifikke humane antistoffer og deres anvendelse
US8119130B2 (en) 2007-07-25 2012-02-21 Medimmune Limited Targeted binding agents directed to KDR and uses thereof—035

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
JPN6013006759; Ｉｎｔ．　Ｊ．　Ｃａｎｃｅｒ Ｖｏｌ．９７, 2002, ｐ．３９３-３９９ *
JPN6013006761; Ｊｏｕｒｎａｌ　ｏｆ　Ａｔｈｅｒｏｓｃｌｅｒｏｓｉｓ　ａｎｄ　Ｔｈｒｏｍｂｏｓｉｓ Ｖｏｌ．１３，　Ｎｏ．３, 2006, ｐ．１３０-１３５ *
JPN6013006764; ＣＡＮＣＥＲ　ＲＥＳＥＡＲＣＨ Ｖｏｌ．６１, 2001, ｐ．７００２-７００８ *

Also Published As

Publication number Publication date
US20100260765A1 (en) 2010-10-14
WO2009013543A2 (en) 2009-01-29
CA2694396A1 (en) 2009-01-29
US8119130B2 (en) 2012-02-21
WO2009013543A3 (en) 2010-05-06
EP2183028A2 (en) 2010-05-12
AU2008278803A1 (en) 2009-01-29

Similar Documents

Publication Publication Date Title
US8119130B2 (en) Targeted binding agents directed to KDR and uses thereof—035
US8663636B2 (en) Method of treating a malignant tumor by administering antibodies directed to DLL4
US7754859B2 (en) Targeted binding agents directed to PDGFR-alpha and uses thereof
US8569459B2 (en) Targeted binding agents directed to sonic hedgehog homolog and uses thereof
US20100196398A1 (en) Targeted binding agents directed to cd105 and uses thereof
US20120107324A1 (en) TARGETED BINDING AGENTS DIRECTED TO a5ß1 AND USES THEREOF
US20120114667A1 (en) TARGETED BINDING AGENTS DIRECTED TO a5BETA1 AND USES THEREOF
JP2012513195A (ja) α５β１に向けられた標的化結合剤およびその使用
AU2015255300A1 (en) Antibodies directed to dll4 and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20101224

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110722

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20110722

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130219

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130513

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130520

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130819

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140204

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20140722